Ligand Pharmaceuticals
LGND
212 hedge funds and large institutions have $1.1B invested in Ligand Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 66 increasing their positions, 74 reducing their positions, and 20 closing their positions.
730% more call options, than puts
Call options by funds: $4.15M | Put options by funds: $500K
85% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 20
16% more capital invested
Capital invested by funds: $953M → $1.1B (+$148M)
7% more funds holding
Funds holding: 198 → 212 (+14)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.07% less ownership
Funds ownership: 87.14% → 87.07% (-0.07%)
11% less repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 74
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCMLC
Cardinal Capital Management LLC (Connecticut)
Greenwich,
Connecticut
|
+$14.4M |
| 2 |
CC
Chicago Capital
Chicago,
Illinois
|
+$9.27M |
| 3 |
ZCM
Ziegler Capital Management
Chicago,
Illinois
|
+$7.66M |
| 4 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$6.39M |
| 5 |
BlackRock
New York
|
+$3.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$11.9M |
| 2 |
Man Group
London,
United Kingdom
|
-$8.04M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$5.69M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$4.64M |
| 5 |
Impax Asset Management Group
London,
United Kingdom
|
-$2.84M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
226
Simplex Trading
Chicago,
Illinois
| – | -$26.2K | -368 | Closed |
|
|
SWA
227
Sutton Wealth Advisors
Tampa,
Florida
| – | -$21.5K | -322 | Closed |
|
228
Ohio Public Employees Retirement System (OPERS)
Columbus,
Ohio
| – | -$11K | -161 | Closed |
|
|
IA
229
IFP Advisors
Tampa,
Florida
| – | -$6K | -30 | Closed |
|
|
USCWA
230
U.S. Capital Wealth Advisors
Austin,
Texas
| – | -$1.87K | -28 | Closed |
|
|
C
231
Covestor
London,
United Kingdom
| – | +$71 | +1 | +50% |
|
|
SFG
232
Steward Financial Group
Colleyville,
Texas
| – | +$213 | +3 | +100% |
|
LGND Hedge Fund Activity: Q1 2023 in Review
212 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q1 2023, worth a combined $1.1B — up 16% from $953M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new LGND positions and 20 closed out — a net gain of 17 holders — while 66 added to existing stakes and 74 trimmed.
The largest buyer was Cardinal Capital Management LLC (Connecticut), opening a new position worth an estimated $14.4M. The largest seller was Millennium Management, cutting an estimated $11.9M.
- 212 institutional investors held Ligand Pharmaceuticals (LGND) as of Q1 2023, up from 198 in Q4 2022.
- Funds reported $1.1B of Ligand Pharmaceuticals stock for Q1 2023, up 16% quarter-over-quarter.
- 37 funds opened new Ligand Pharmaceuticals positions in Q1 2023 and 20 closed out, a net change of +17 holders.
- The largest Ligand Pharmaceuticals buyer in Q1 2023 was Cardinal Capital Management LLC (Connecticut), an estimated $14.4M added.
- The largest Ligand Pharmaceuticals seller in Q1 2023 was Millennium Management, an estimated $11.9M sold.
Based on aggregated 13F filings for Q1 2023.